In a recent publication from Toxicologic Pathology, Neurosetta’s RosetteArray technology was highlighted as an exemplar of a complex in vitro model (CIVMs) that offers the potential to increase the clinical relevance toxicity assessments and reduce the reliance on animals in drug development.
